AYA Share Price Performance
AU$0
-2.23 (-100.00%)
Price AU$0
Fair ValueAU$5.96
Share Pricen/a
Artrya Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
AYA Community Narratives
AN
Fair Value
·Fair Value AU$5.96 45.1% undervalued intrinsic discount
US CCTA Adoption And New Reimbursement Will Drive Long Term Cardiac AI Potential
1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Artrya
45.1% undervalued intrinsic discount
US CCTA Adoption And New Reimbursement Will Drive Long Term Cardiac AI Potential
View narrativeAN
Updated 31 Jul
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
AYA: New CFO Appointment Will Support Future Earnings Re Rating
Fair Value: AU$5.96 45.1% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
Snowflake Analysis
Artrya Limited Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.15
- -71,496.43%
- -89,939.29%
- 0%
About AYA
- Founded
- 2018
- Employees
- n/a
- CEO
- WebsiteView website
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. It offers Salix, a suite of cloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. The company was incorporated in 2018 and is based in West Perth, Australia.
